Literature DB >> 34636907

Anti-SARS-CoV-2 IgA Identifies Asymptomatic Infection in First Responders.

Brian T Montague1, Matthew F Wipperman2, Andrea T Hooper2, Sara C Hamon2, Rowena Crow1, Femi Elemo2, Lisa Hersh2, Shaun Langdon2, Jennifer D Hamilton2, Meagan P O'Brien2, Eric A F Simões1.   

Abstract

BACKGROUND: Immunoglobulin A (IgA) is an important component of the early immune response to SARS-CoV-2. Prior serosurveys in high-risk groups employing IgG testing alone have provided discordant estimates. The potential added benefit of IgA in serosurveys has not been established.
METHODS: Longitudinal serosurvey of first responders (police, emergency medical service providers, fire fighters, and other staff) employing 3 serologic tests (anti-spike IgA, anti-spike IgG, and anti-nucleocapsid IgG) correlated with surveys assessing occupational and nonoccupational risk, exposure to COVID-19, and illnesses consistent with COVID-19.
RESULTS: Twelve percent of first responders in Colorado at baseline and 22% at follow-up were assessed as having SARS-CoV-2 infection. Five percent at baseline and 6% at follow-up were seropositive only for IgA. Among those IgA positive only at baseline, the majority (69%) had a positive antibody at follow-up; 45% of those infected at baseline and 33% at follow-up were asymptomatic. At all time points, the estimated cumulative incidence in our study was higher than that in the general population.
CONCLUSIONS: First responders are at high risk of infection with SARS-CoV-2. IgA testing identified a significant portion of cases missed by IgG testing and its use as part of serologic surveys may improve retrospective identification of asymptomatic infection.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; IgA; SARS-CoV-2; cumulative incidence; epidemiology; first responders; serosurvey

Mesh:

Substances:

Year:  2022        PMID: 34636907      PMCID: PMC8549282          DOI: 10.1093/infdis/jiab524

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  1 in total

1.  Elevated serum IgA following vaccination against SARS-CoV-2 in a cohort of high-risk first responders.

Authors:  Brian T Montague; Matthew F Wipperman; Erica Chio; Rowena Crow; Andrea T Hooper; Meagan P O'Brien; Eric A F Simões
Journal:  Sci Rep       Date:  2022-09-02       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.